Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Cantargia, Audiocast with teleconference, Q2'24

By Inderes8/28/2024, 1:00 PM
Cantargia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

John
00:00 - 18:34

Thank you. It's a pleasure to present Cantargia's half-year report for what I think has been a very exciting period in the company. So, to take you into the highlights, we've had a very good news flow regarding both our clinical programs. The company passed a number of important milestones during the period. So we have almost completed the initial phase of the phase one trial. And the SAD means when single dosing, and we've had the independent safety review and unblinded data that has not picked up any safety concerns. So the safety is obviously very good on Cantargia. Uh, we've also started to generate biomarker data, which shows that we have a very potent drug. For instance, we've documented receptor binding onto the target D1, RAF on immune cells at a relatively early and predictive dose level. And we also generate strong biomarker data. We'll present more about that when we go through the slides later on. And there have also been several scientific publications with new data. So obviously, that's also creating additional interest in the oncology program. Additionally, we have presented data at several conferences. So, we presented new data on pancreatic cancer, showing additional features on anti-fibrotic effects. We have new clinical results on the prevention of neuropathy. And we also looked into the fact that there is actually a link between KRAS mutations, which are a major problem in pancreatic cancer, and how it fits very nicely with our mechanism of action. And finally, we have made it. We are making progress in the upcoming leukemia trial, and we are also starting to see the end of recruitment in our triple-negative breast cancer trial. And finally, we also have a much cleaner sheet now when it comes to our patents, where the latest appeals against our granted patents were withdrawn ahead of proceedings. It was certainly a good period. So, just to remind you then, on our pipeline. So, to basically make it simple. We have two clinical programs now. The only models where we have mouse data are in pancreatic cancer, triple-negative breast cancer, and non-small cell lung cancer. Continuing, we have our second program content, which is currently in phase one. The plan is to enter Phase 2 in the second half of next year. Once we're through the main part and the lead indications, here we have a small update: we're generating more and more support to move into a serious dermatological disease called Hydrogenated Super Diva. So, that's clearly on our radar. And the second indication we're targeting is systemic sclerosis, which is also a very serious fibrotic disease affecting the skin, lungs, and internal organs. I am very excited about these two opportunities. And we also have the potential to broaden our pipeline over time, as we launch our next program with new opportunities in both disease areas and bispecific antibodies. So, very quickly then, we have had a good quarter. We have high expectations for the rest of the year and next year as well. To continue generating data in our two clinical programs, we have several milestones ahead of us. And I think as an investor, you should also expect that we are visible when it comes to publications and conference presentations of new data. Starting with the content, this is really where we have made significant progress lately. So to just take you through our biology, first, a campaign is targeting what's called the IL1 family of cytokines, and the IL1 family of cytokines are driving several inflammatory diseases. The potential in content is enormous, and we are really faced with more opportunities than we can handle. As I said, we've decided to look into HS and systemic sclerosis as early indications. Uh, the really key feature here is that if you look at the bottom up slide, it is that content is through its interaction with IL1RAP. One representative is blocking the activity of three different cytokine systems. You have the VL 33 system as well as the Trial 46 system. And they are all responsible for driving several diseases. But very often they work together, and that has been very clear when you try to block them individually. But in most cases, it has been very difficult to obtain strong, meaningful clinical signals. And it's just because you're talking about one of several compounds driving the disease. And if you look to the bottom and to the right, we're trying to illustrate this in an in vitro experiment where we are basically looking at the signal induced by a mix of IL1 alpha, three, and alpha six. And if you then try to block them individually, like always black lines, you can see that there is very little potency in blocking either alpha 2,3 or alpha 2,6 individually. But if you use a compound like the one shown here, suddenly you have a highly potent molecule that is active at sub-nanometer levels. So clearly, a major step forward here. So, moving on to the next slide. The phase one has progressed very well and very timely. So, the trial is designed as intravenous administration in the first part, involving healthy volunteers. So that's the sad part. We have really seen a very good safety. Uh, we've seen receptor occupancy. And that's illustrated at the top here to the right where we can look at the binding of CAN10 to either monocytes or neutrophils, two different types of immune cells in the blood. And if you look at what's called Z1 and Z2 to the left, that's the very low dose levels of the content. So obviously the dose levels are too low to document anything, but as we increase those levels inside three and upwards, you can start to see that we are saturating IL1RAP on these immune cells. So, this is very much in line with our predictions. But the next step, which has increased enthusiasm even more, is that we have collected blood samples from these individuals. And you can see it in the bottom here. We stimulated the blood with IL-36, and observed effects both before and after administering a single shot. And then we analyzed the viability for IL1RAP to stimulate the cells eight days after they were contained. And you can see that there is a nice dose-response here as well. So at Z5, it's clear that we already have a very potent inhibitory effect, which is then getting stronger and stronger at Z7. We blocked the alley 5 to 6 signals, so it shows that Cantargia is doing its work. And this provides an extended effect for at least a week afterwards. So, we are very excited about this and are now equally thrilled as we start the MAT report, which is conducted in participants with mild or moderate plaque psoriasis. And so it gives us another opportunity to learn even more as we can obtain skin biopsies from these patients in addition to what we can already measure in the blood. And we expect the first individual to start treatment any day now. Uh, very good progress in this phase one trial. As I mentioned, we are already planning for Phase 2 to ensure that it can start as quickly as possible once Phase 1 is completed, sometime during H2. So then, just a comment on hydrogen. It is imperative because I am sure not everyone is extremely familiar with it, but it is a very complex disease that starts out as an inflammation and then progressively worsens inside the skin. What's interesting is that there is documentation addressing all the components. Cytokines IL-1, IL-6, and TNF-alpha are all upregulated in the skin from these patients. Recently, there was clinical data presented on IL1RAP blockade using data from above to reach the primary endpoint in a controlled phase two trial, and the results were strong enough for Cantargia to start phase three, which began earlier this summer. And in parallel, Boehringer Ingelheim is developing an antibody against IL1RAP, which also showed positive results in a phase two randomized trial. Boehringer Ingelheim is also continuing the development. So our anticipation here is that the very positive data from the Kaiser map, especially on some parts of the disease, combined with what use Boehringer Ingelheim saw with specific Mab, can be added together. And that can then combine all these features into one product. We are super excited about this. And also, it is a very common disease. It's estimated that around 1% of the European and US population suffers from it right now. And it's increasing. So, to summarize a bit, it has been shown that IL1RAP blockade can counteract the inflammation. It's also been shown that the Alpha-six blockade from Boehringer Ingelheim is affecting something called the draining tunnels, which is an important part of the disease development. And more speculatively, IL1RAP is involved. We know that from other diseases. It's a contributor to serious itch. And even though there is no data, we have a strong belief that blocking alpha-3 through content will also have an effect on that, which means that content can actually attack very different parts of this serious disease. So then moving over to Nadunolimab. We have previously presented data in pancreatic cancer, which clearly indicates a treatment effect. And with notable survival data in first-line patients where we combine with gemcitabine, a vaccine, which is part of it as standard therapy. And we have also shown that the more IL1RAP the patients have in the tumor, the stronger efficacy we can observe from this combination. And this is exciting as a high IL1RAP is associated with a worse prognosis from KRAS mutations. So if you look to the left here, you can see that the survival is about 14.2 months in the high IL1RAP group versus 10.6 months in the lower IL1RAP group. And also if you look at the spider plots to the right, you can see that here in the middle where you have IL1RAP high patients, they respond to the therapy in a stronger way, but also that the responses are much more durable. So you can see that you have patients that have been in response for almost one and a half or two years, while the real IL1RAP group, they typically deteriorate after six months. So again, a very positive result in pancreatic cancer, which is obviously a very difficult disease to treat. And we are planning to take these findings forward into a phase 2B trial. But another interesting observation from this trial, which was presented during the period, is that not only do we have an interesting anti-tumor effect, but we also seem to alleviate a serious side effect from the chemotherapy combination partner, which is neuropathy. So if you look to the left, that's data from the clinical trial. You can see that the patients that were treated with Nadunolimab, which is the gray bar here, developed much more neuropathy and also got the onset of neuropathy earlier than patients that received the higher dose levels of 2.5 or above. And to remember, 2.5 is the dose level we are targeting in future clinical trials. And to the right, we also have a collaboration with the group in Brisbane, Australia, who have been investigating mouse models of chemotherapy-induced neuropathy. And again, we can see that Nadunolimab doesn't seem to counteract with neuropathy. It could be sensitivity to mechanical pressure, or it could be grip strength. Nadunolimab does not seem to do a very good job here to counteract this very unpleasant side effect. And then to remind everyone that besides pancreatic cancer, we're also working in triple-negative breast cancer. The initial part of the trial has been presented as it was, a non-controlled dose-finding study. And here we can see a 60% response rate. And which is about twice as high as expected from chemotherapy alone. And again, this is chemotherapy combination for first and second line patients. And the survival was also longer. And the progression-free survival was longer than expected from historical controls. So we're very excited to start to deliver these results. And we're looking to do that in the first half of next year. So to quickly summarize the biology here in this I apologize because this is a slide which may be a bit difficult to read. But the point here is that if you look to the left, you'll see this biological mess that illustrates what's happening in the tumor. Nadunolimab can block signals at all these different red crosses here, which is leading to various types of tumor-promoting signals. And then, if you look very carefully, you can see that there are some yellow parts here which indicate IL1RAP overexpression. This antibody has been designed to stimulate immune cells to attack these tumor-promoting cells. So the drug is active at a large number of different sites to effectively block tumor progression. And at the same time, it's interesting that the same signals can then be used to counteract neuropathy, as illustrated here, at the lower part of a leg, where you can see red crosses blocking some inflammatory mechanisms that lead to the unbearable pain of neuropathy. So that reflects the progress, but also reflects a little bit of what's going to come here during the next part of the year. So, I would like to hand it over to Patrick, who can go through the financial report.

Patrick
18:35 - 22:40

Yes. You're on. And, I'm going to take you quickly through the financial highlights. Um, as you can see, it's quite the opposite. We have a 30% reduction in our operating expenses in the second quarter, where we went from 63 million in 2023 to 44 million this year. And it's driven, as you can see, by R&D. So we dropped from 17 million to 40 million SEK in the quarter. And our cost for administration. In this report, we combine the data presented in the graph with other operating expenses. Our main administration costs were unchanged, but we had lower other operating expenses, which then reduced the total by 2 million from 6 to 4 in the quarter. And then if we look at the results for the first half year, we had a 39% reduction in operating expenses, from 142 to 85. Again, obviously driven by R&D. Um, and if I just take two seconds to explain what's behind that, it's the fact that we are now running two clinical trials. As you mentioned, we are conducting the triple negative breast cancer (TNBC) study with National Lab TRI4. And, we are actively recruiting for the cancer clinical trial, the first study in humans. Whereas in the same period last year, we had a full program for National Lab, with studies that are still active. They are still active, but from a financial point of view, we are about to reconcile. And, eventually close them down. So to clarify, we have been able to reduce our administrative costs by 1 million in the first six months. The reduction from 11 to 7 includes operating expenses that were lower. All in all, we reported operating expenses of 85, as you can see there. All in all, the net loss was 80 million as we had 5 million in financial gains. Net financial items were positive. 5 million. So, we also report on the development of our available funds, which are of course important and available. Funds are important because they fund all the activities we undertake, and we track available funds. Repeating, this is the sum of what we report as cash, bank balances, and short-term investments. These are primarily fixed-term funds with set interest rates. We concluded the six-month period at the end of June. We had 105 million in available funds, which represents a decrease of 38 million, which was lower than the 52-million decrease observed from the fourth quarter of 2023 to the first quarter of this year. So, we expect that the 105 million that we now have will suffice through to the first quarter of next year. Or, if we make prioritizations, We can extend that to

Unknown 1
22:41 - 22:41

the

Patrick
22:41 - 22:47

first half of next year. And with that, I hand back over to you, John.

John
22:50 - 25:50

Thank you. I would just like to finish off here by showing some of the upcoming milestones. When I manage the program, there are many activities currently ongoing. We have a pancreatic cancer trial that is still pending financing, but we are engaged in several promising discussions regarding our pipeline. However, the plan is to start the phase 2B trial, which will be a large trial involving 150 to 200 patients, as quickly as we can. We have triple-negative breast cancer data where recruitment is ongoing, but we expect randomized data to be released during the first half of next year. We are also very excited about the grant from the US Department of Defense to sponsor the upcoming trial in leukemia, AML, and MDS, and the VA. As you may have seen from the communication, what was approved recently, we expect the ethics approval to be completed soon, which will then allow the site to start recruiting patients during Q4. So, exciting progress and much more to come. The content program has obviously generated a lot of interesting data from the study. In 2024, our intention is to continue to be transparent as we reach significant progress. What we now have in front of us is the start of the multiple dosing part, where we believe that we will add another layer of excitement to the data as we can now collect tissue from participants with psoriasis. The plan is then to go ahead and file in the US and start phase two next year. We also have a number of clinical trials where, as we continue, we will get long-term follow-up of patients, and in the near future, we are presenting new data on lung cancer as well as on the Keytruda combination at the asthma conference. And I'm sure there will be more data at upcoming conferences, both in 2024 and 2025, from this program. So with that, I'd like to thank you for your attention. Patrick and I are extremely happy to provide additional clarifications or take questions afterwards.

Operator
25:53 - 26:21

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Victor Sundberg from Nordica. Thank you for joining today's webcast, where we will be discussing Cantargia's performance and strategic outlook for the second quarter and first half of the year 2024.

Victoria
26:22 - 27:54

Yes, hello and thanks for taking some questions. Um, I'll ask a couple of questions all at once. Um, so first off, I just wanted to understand a bit more about the delay on the Triforce study. Just wanted to understand a bit more why recruitment slowed down a bit during the summer. Was it due to competition in triple negative trials, lack of interest, vacations, or other factors? Any detail there would be really helpful. Secondly, on CAN10 and your ambition to address systemic sclerosis. I just wanted to understand a bit more about what could differentiate your drugs against the up-and-coming 36 drugs, such as BVO and EMC Mab, and what unmet needs you aim to address with currently approved drugs such as those targeting IL-17 and TNF-alpha inhibitors, etc.? Is it mainly improved efficacy, or do you also see any safety concerns with the currently up-and-coming drugs? And maybe a quick comment on the pros and cons of hitting several interleukins versus specific inhibition. And finally, on the cost for the full year. Your R&D expenses have significantly decreased, as indicated in your report. Year over year, but just focusing on the second half of the year. Are there any one-time payments to zeros that you know of today that we should factor in, which could increase R&D here in the second half? And also given your runway, is it still feasible to drive for results before you need to raise cash? I appreciate having the opportunity to address these questions. Thanks.

John
27:56 - 31:43

Yes, thank you Victoria. I agree, lots of questions and hopefully I got it all now. But you have to remind me if I forget something; it's not intentional, so I try to avoid delays. So we are working with Gcam, who is our partner's parent company, to understand more about why recruitment slowed down during summer. Uh, but we noted the same thing last summer in the US. Uh, clinical trials holiday. It has had an effect on recruitment, but it was, let's say, more pronounced this year. So, I don't have a good answer on all parts of the background here and how much competition is involved. But we are following up, and it's likely several factors behind this. But we also believe that guiding for H1 gives us, let's say, good room to maneuver and ensure that we deliver on this milestone for when for content in HS. As you rightly pointed out, patients with HS currently have various treatment options available. Uh, but reality is that, uh. It's a ballpark number. It's somewhere 50% or slightly higher numbers that respond to these therapies. So you have a huge unmet need here in patients who are not responding to these therapies. And we clearly believe that we can do this better. And again, if you look at IL1RAP likelihood Nadunolimab and or IL 36, it's not that they individually have provided much stronger efficacy than anti-TNF and anti-IL-17. But the interesting part of Anti-IL-1 is that it has shown efficacy in patients that are no longer responding to anti-TNF PFS, but with very complex biology. We believe that we can beat those two when it comes to efficacy and long-term effects by attacking both the draining tunnels itch potentially, as well as the general inflammation. Uh, and then you asked about pros and cons of, uh, taking several versus individual cytokines. I clearly believe that as long as it is good and we have not picked up any major. So it's safety concerns. And we're not expecting major safety concerns by blocking A123 and Alpha six at the same time and again IL-1 blockade is safe. Alpha six blockade is safe. So we believe it's going to be an efficacy argument at the end of the day, which we hope to lead against cancer. But it's a complex disease and there is room for several treatments for sure. And so hopefully, I answered those two questions. And then I suggest that Patrick takes, uh, the costs question.

Unknown 1
31:43 - 31:44

Yeah.

Patrick
31:44 - 32:23

Um, are there any significant payments to cross or suppliers scheduled for the second half of the year? I think that was the question. And it's nothing out of the ordinary. We are running the two trials that we have communicated or I have mentioned and there's nothing abnormal there, nothing extraordinary planned. Um, and then, uh, the cost driver, I think, we should perhaps take that as a question for our financing here, and I'm not sure if you want to.

Unknown 1
32:25 - 32:26

Just.

Patrick
32:26 - 32:27

Take that.

John
32:27 - 33:04

No, but clearly we understand that we're in the biotech business. And there's always a constant need for financing. And the situation we're in right now is that we have several different ongoing discussions. And it's very tough to be concrete about what they are until they have reached the goal. So, but uh, so I cannot comment any further. But we have several options and I think that's what's important right now.

Victoria
33:07 - 33:08

Okay. Thank you very much.

Unknown 2
33:10 - 33:10

Thank you.

Operator
33:15 - 33:20

The next question comes from Richard Romanus from RedEye. Thank you all for joining us today for Cantargia's Q2 and half-year report for 2024.

Richard Romanus
33:24 - 33:51

Hello, everyone. Good afternoon. Could you tell us, more or less, where you are? At what stage are you in with the triple negative breast cancer clinical trials? Could you say how many patients you've recruited for us? And, in relation to the same study, what data can we expect to see? How many patients are expected in H1 2025, and from how many countries, for example?

John
33:54 - 34:52

Yes, the majority of patients have been recruited to date, and we believe that the trial will be fully recruited sometime during Q1, as it looks right now in the prognosis. And, uh, the intention is to communicate, let's say, early-stage efficacy data as well as safety data. So that would be response rates, as quickly as possible. Once we have that data on patients in the trial. So it will not be the complete data set, but it will certainly be a very material data set based on all patients in the trial. However, it will not contain the long-term follow-up.

Richard Romanus
34:54 - 35:16

Okay. Could you discuss how your plans look when you have full data from placebo-controlled trials in triple negative breast cancer? What you're going to do with them because I assume that would help you in partnering discussions, for example.

John
35:18 - 36:27

No, but I think they are a very important part of, let's say, a more. Complex picture here. So, clearly obtaining randomized data will give us a necessary and important signal to prove that the drug is active in such a setting. Uh, and then obviously, where we see a very huge commercial opportunity is in pancreatic cancer. So, where the competition is much lower. It is a combination of obtaining randomized data in one cancer disease and then using that as a trigger to build a complete story, understanding the mechanism of action, and significantly increasing the chances of forming a partnership.

Richard Romanus
36:30 - 36:50

Okay, so I lost my last question, but I have a quick follow-up. Do you think the pancreatic cancer trials will start before the first results in triple negative breast cancer or afterwards? Could this be a signal that it might also work in pancreatic cancer?

Unknown 1
36:52 - 36:53

No, but.

John
36:53 - 37:15

My desire is to start the pancreatic cancer trial ahead of receiving the results in triple-negative breast cancer. I believe that we have a very interesting case in pancreatic cancer, and I'm always a little bit impatient. So, I'd like to start as quickly as we possibly can.

Richard Romanus
37:18 - 37:19

Thank you for joining us today for the Cantargia Q2 and half-year report webcast for the year 2024.

Operator
37:19 - 37:33

Thank you. The next question comes from Luisa Morgado from Van Kempen. Welcome everyone to today’s webcast on Cantargia's Q2 and half-year report for 2024.

Tim
37:37 - 38:15

Hi, Tim. Thank you for taking our questions. Uh, from our side, two questions. The first one regarding the current cash for cash runway. Um, how far along does this take? You know, the different programs? Are you willing or are you trying to prioritize here, not focusing solely on mountain content development equally? And secondly, could you elaborate a bit more on the results that you will present at ESMO in September? And is this the only conference in 2024 where you will be presenting new data?

John
38:16 - 38:24

Thank you, Patrick, will you start with the cash question?

Patrick
38:25 - 39:27

The prioritization between our two clinical programs was the focus. We have two wonderful children, and we don't prioritize. Between them, we focus on the most value-adding activities, regardless of whether it's Nadunolimab or CAN10. And when we decide where to invest. But I think right now we have the ongoing clinical studies. Those are the two most important activities that we have. We make sure that we allocate our funds appropriately and reprioritize other activities that can wait if we are constrained for cash, and we are always constrained for cash. But, that's my answer to the prioritization question. Um, what? Was it only one?

Tim
39:28 - 39:38

Indeed, regarding these two programs, which activities are currently included in this cash runway?

Unknown 3
39:38 - 39:40

No, no. So, it's the ongoing, um.

Patrick
39:41 - 39:52

First and foremost, the human aspect is prioritized, and we are not investing in new activities. And until we have secured financing, for sure.

Operator
40:01 - 40:07

The next question comes from Sten Westerberg from Analyst Guidance. Welcome to today's Cantargia webcast, where we will discuss the Q2 and half-year results for 2024.

Unknown 4
40:12 - 41:15

Good afternoon to all of you. And, um, a question regarding if you could share some more of your thoughts on a potential PDAC study. For example, you've been historically alluding to the possibility of some risk sharing, or the fact that you may carry out the study entirely on your own. And how confident are you that you will end up with the maximum tolerated dose in this study? That would be all my questions. Thank you.

Unknown 2
41:18 - 41:18

Yeah.

John
41:19 - 41:31

So, if we start with the PDF studies then. So, I think we are currently looking into several opportunities here.

Unknown 1
41:33 - 41:33

Which.

John
41:33 - 43:24

It could involve some kind of risk-sharing, co-development, or partnership versus doing it ourselves. Better ongoing discussions, but nothing concrete yet. So I will note that it's impossible to guide which way we will go. The only thing I can say is that we strongly believe in our data. When we present data to experts, they are also excited about the signals. So, let's see where we are getting. The second one on the contents. The way it's done is that wizard doses are quite straightforward. The specific scheme that we are currently examining is Group Nine, which includes 400 million units of antibody. Then, for the medication dosing, that takes into account the pharmacokinetics measured in the third part. So, typically, we are dosing slightly above 100 right now in the first Mad cohort. If we reach the maximum tolerated dose, I believe this will indicate a highly active and efficient level.

Unknown 2
43:26 - 43:30

So yeah, please follow up.

Unknown 4
43:30 - 43:39

So, just a quick follow-up. Are you in any way surprised that you haven't seen any safety signals so far in the dosing?

John
43:41 - 44:17

No, I would have been surprised if we had not picked up anything in our toxicology studies. Ah, that could be of relevance here. And we also have significant information from the National Cancer Map, which in a way could be regarded as probably, if anything, a slightly more toxic variant of cancer. But we have no major safety signals here either. No, we didn't expect to see any safety concerns at the levels we are at right now.

Unknown 4
44:21 - 44:22

Thank you.

John
44:22 - 44:30

But then, to underline, it's much better to have data to show that you don't see any safety signals when guessing.

Unknown 1
44:34 - 44:34

Fair enough.

Unknown 4
44:36 - 44:37

Thank you.

Operator
44:43 - 44:49

The next question comes from Arvid Nkunda from Carnegie. Please go ahead.

Arvid Nkunda
44:52 - 45:39

Good afternoon and thanks for taking my questions. A couple, if I may. First of all, you've put forward some data, suggesting a correlation between KRAS mutations and an activated L1 system in pancreatic cancers. KRAS inhibitors are now making some strides, perhaps most notably with Revolution Medicines. Moving into phase three, albeit in the second line setting, as I understand it. Has this in any way influenced your development strategy? And given the high prevalence of KRAS mutations in pancreatic cancer, Where do you see the main opportunity for differentiation? Assuming that their data holds up? Um, and then secondly,

Richard Romanus
45:39 - 45:40

If just,

Arvid Nkunda
45:40 - 45:56

Is there anything you can share on your partnering strategy for your content, how actively are you pursuing partnerships at this stage? And, is this something you see ramping up significantly once the phase one is concluded next year? Thanks.

John
45:58 - 46:22

Yeah. So, thank you. I had a great question. So it's absolutely right that Revolution Medicines has generated some interesting data, Targeting KRAS mutations. It has not affected our development strategies right now.

Unknown 1
46:22 - 46:23

But,

John
46:24 - 47:27

Certainly, I think if anything, it strengthens the whole case and in the future, you could probably argue that a combination here could be a very potent way forward where you both attack the mutation and some downstream effects of the KRAS mutations. One issue with KRAS when you're attacking them is that the responses are relatively short-lived because, once you attack one mutation, new mutations come up. So having a second mechanism, which blocks the consequences of all these mutations, I think it's a super interesting and exciting way forward. But right now, I think,

Unknown 1
47:29 - 47:29

It.

John
47:30 - 48:36

Various new medications are needed in pancreatic cancer. So I think what we're really focusing on is advancing our own program, in a first-line chemo combination. And the second question relates to a partnering strategy for content. So, as Cantargia is evolving right now, we have programs in phase or entering phase two in both oncology and inflammation. And it makes a lot of sense to partner one of these programs and focus our attention on the second leg. Hopefully, the partnering will also add valuable financing to the development program. And at this point in time, I'm pragmatic about whether the content is likely going to partner first or if it's going to map the way forward.

Richard Romanus
48:41 - 48:43

Okay, great.

Operator
48:47 - 48:55

There are no more questions at this time. So I hand the conference back to the speakers for any written questions or closing comments.

Unknown 2
48:59 - 49:23

There are a couple of questions coming in from the web, and the first one is partly answered, I guess, but the questioner wonders why. It seems like you have shifted focus from having to start up the study this summer to awaiting results from the triple negative breast cancer and the CAN10 study before deciding how to proceed.

John
49:26 - 50:03

Now, we have not changed our strategy, but as we enter the mid to late stages of clinical trials, the financial needs obviously get higher and higher. It's crucial for us to conduct this trial, ensuring that we are not only financed but also financed in a manner that makes sense to the shareholders. Therefore, we strive to be patient in finding the best possible solutions moving forward.

Unknown 2
50:04 - 50:16

Yes. And in connection with that, the questionnaires. Also wondering whether it's correct that you need to secure an additional 250 million in funds before starting the study.

John
50:20 - 51:10

So, if it's 250 or whatever it is, it remains to be seen. But if you proceed with this type of trial, where the cost per patient is assumed to be 1 million SEK or above, you clearly need to have substantial financing in place. And you obviously also need a way to either continue full recruitment with additional financing or find a way to step out of the trial while still generating meaningful results. So again, I think it's very much a question of being responsible in how you finance these trials.

Unknown 2
51:12 - 51:30

Thanks. Could you elaborate a bit more on what you're expecting from them, and also maybe define what you mean by 'near term' in that respect? When will you be getting these results?

John
51:32 - 52:38

So, I'm not sure if it's a question more specific about readouts. Otherwise, I can be more general. So I think the way Cantargia has been operating when it comes to clinical trials is that we're trying to secure robustness in the data sets, and then we communicate it. And then, obviously, there are always long-term follow-ups along the way. So if you take, for instance, the triple negative breast cancer, it has a major readout in the near future. We will always communicate the safety at that given time point. And the plan is now that, since not all patients have long-term efficacy data, we will focus on the short-term efficacy, where we can ensure that we have robust data, and then we will present the long-term efficacy data. I don't know, half a year later or whatever, or once we have more robust data.

Unknown 2
52:41 - 52:45

Thanks. That was all coming in from the web.

John
52:48 - 55:00

Thanks. And I realize that I have one question which was asked earlier about guidance for what we are planning to present at ESMO and if there are more conferences during the year. So at this ESMO, it will be data on the Keytruda combination. We have presented an earlier data set, which showed, let's say, safety and short-term effects of the combination. We now have much more robust survival data. We have much more robust progression-free survival data. And we can link all this to the extensive biomarker analysis that has been done and that will be presented in one poster. The second poster relates to non-small cell lung cancer (NSCLC). As you may recall, we have presented data on 30 patients receiving combination therapy as first line and second line patients getting combinations with gemcitabine and cisplatin. The trial then added another ten patients receiving Pemetrexed plus platinum. So that data set will be incorporated, and we will present more on biomarkers and subgroup analysis at the conference. The plan is to present more data from other trials or another program later on this year. So by that, I'd like to thank everyone for your attention, and I'd like to thank you for your interest with lots of very good and relevant questions. And I hope you're just as excited as I am about the autumn and the upcoming milestones. So I really look forward to continuing to work here, to deliver results, and to the Q3 call in a few months time. So thanks a lot.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…